Eli Lilly & Co. (LLY) beat expectations in Q2 FY2026 on revenue of $23.0B versus the $20.8B estimate (+47.7% YoY) and EPS of $8.38. The next Eli Lilly & Co. (LLY) earnings date is Oct 29, 2026. Below is the full Eli Lilly & Co. earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
Eli Lilly & Co. (LLY) Earnings Analysis — key stats
Next earnings date
Oct 29, 2026
Latest reported quarter
Q2 FY2026
Earnings verdict
Beat
EPS beat rate
7 of last 8 (quarters above estimate)
Avg next-day move
±8.1% (over the last 8 reports)
Post-earnings direction
Up 5 / Down 3 (of the last 8 reports)
Implied move (next report)
±17.9% (options-derived · into Oct 29, 2026)
Institutional ownership
251.8% (13F as of 2026-06-30)
Top 10 holders
45.4% (of shares outstanding)
Insider activity
7 buys / 5 sells (recent Form 4 filings)
Revenue
$23.0B (vs $20.8B est · +10.3% surprise · +47.7% YoY)
EPS
$8.38 (vs $6.40 est · +30.9% surprise · +26.2% YoY)
Share price
$1247.92 (-0.6%)
Market cap
$1.18T
Eli Lilly & Co. (LLY) Earnings Analysis — beat / miss history
Quarter
Revenue
EPS
EPS surprise
Next-day move
Verdict
Q3 FY2026
$23.0B vs $20.8B est
$8.38 vs $6.40 est
+30.9%
+6.8%
Beat
Q2 FY2026
$19.8B vs $17.8B est
$8.55 vs $6.97 est
+22.7%
+13.2%
Beat
Q1 FY2026
$19.3B vs $17.9B est
$7.54 vs $6.91 est
+9.1%
+1.7%
Beat
Q4 FY2025
$17.6B vs $16.1B est
$7.02 vs $5.69 est
+23.4%
+6.1%
Beat
Q3 FY2025
$15.6B vs $14.7B est
$6.31 vs $5.60 est
+12.7%
-16.2%
Beat
Q2 FY2025
$12.7B vs $12.7B est
$3.34 vs $3.26 est
+2.5%
-8.4%
Mixed
Q1 FY2025
$13.5B
$5.32 vs $5.03 est
+5.8%
+4.3%
—
Q4 FY2024
$11.4B vs $12.1B est
$1.18 vs $1.47 est
-19.7%
-8.2%
Miss
Top institutional holders
Holder
% outstanding
Shares
Value
QoQ change
Lilly Endowment INC
10.1%
90.4M
$108.4B
-1.7%
Blackrock, INC.
7.6%
67.5M
$81.0B
+1.7%
Vanguard Capital Management LLC
6.0%
53.5M
$64.2B
+0.3%
Pnc Financial Services Group, INC.
5.7%
51.3M
$61.6B
-0.0%
State Street Corp
4.0%
36.2M
$43.4B
+1.7%
Fmr LLC
3.2%
28.5M
$34.1B
+8.1%
Capital Research Global Investors
2.3%
20.9M
$25.0B
-15.3%
Vanguard Portfolio Management LLC
2.3%
20.9M
$25.0B
-0.6%
Geode Capital Management, LLC
2.3%
20.3M
$24.3B
+0.6%
Morgan Stanley
1.8%
16.2M
$19.5B
+5.1%
Recent insider transactions
Insider
Role
Date
Type
Shares
Value
Sulzberger Gabrielle
director
2026-08-17
Buy
4
$4958
LUCIANO JUAN R
director
2026-08-17
Buy
13
$15917
Fyrwald J Erik
director
2026-08-17
Buy
8
$9917
Alvarez Ralph
director
2026-08-17
Buy
10
$12417
Jonsson Patrik
officer: EVP & President, LLY Int'l
2026-08-17
Sell
7K
$7.6M
Zakrowski Donald A
officer: SVP, Finance, & CAO
2026-08-10
Sell
2K
$2.4M
Hakim Anat
officer: EVP, GC & Secretary
2026-08-07
Sell
5K
$6.0M
Seymour Melissa
officer: EVP, Global Quality
2026-08-01
Buy
981
—
What you'll find
Next Eli Lilly & Co. (LLY) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Eli Lilly & Co. reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Eli Lilly & Co. (LLY)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Eli Lilly & Co.'s next earnings date?
Eli Lilly & Co.'s (LLY) next scheduled earnings date is Oct 29, 2026. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Eli Lilly & Co. (LLY) beat or miss earnings?
In Q2 FY2026, Eli Lilly & Co. (LLY) posted beat results — revenue of $23.0B versus the $20.8B estimate (+10.3% surprise) and EPS of $8.38 versus $6.40 expected (+30.9% surprise). Magnisto decodes every Eli Lilly & Co. (LLY) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
How often does Eli Lilly & Co. beat earnings estimates?
Over its last 8 reported quarters, Eli Lilly & Co. (LLY) beat Wall Street EPS estimates 7 times, most recently a beat result in Q3 FY2026. Magnisto tracks every Eli Lilly & Co. (LLY) quarter's revenue and EPS versus consensus and grades each one Beat, Miss, In-line or Mixed at a unified ±2% threshold.
How much does Eli Lilly & Co. stock move after earnings?
Over its last 8 quarterly reports, Eli Lilly & Co. (LLY) moved an average of ±8.1% the day after earnings — ranging from -16.2% (Q3 FY2025) to +13.2% (Q2 FY2026). The stock rose after 5 of those 8 reports and fell after 3. Heading into its next report on Oct 29, 2026, options-implied volatility is pricing in a move of roughly ±17.9% (derived). Magnisto tracks the realized post-earnings move for every Eli Lilly & Co. (LLY) quarter alongside the beat/miss verdict — past moves don't predict the next one.
Who are the largest shareholders of Eli Lilly & Co.?
Institutions hold about 251.8% of Eli Lilly & Co.'s (LLY) shares outstanding as of the 2026-06-30 13F quarter. Its largest institutional holders include Lilly Endowment INC (10.1%), Blackrock, INC. (7.6%), Vanguard Capital Management LLC (6.0%). Magnisto lists Eli Lilly & Co.'s (LLY) top 13F holders with each stake size and its quarter-over-quarter change.
Are insiders buying or selling Eli Lilly & Co. (LLY)?
In the most recent Form 4 filings Magnisto tracks, Eli Lilly & Co. (LLY) insiders recorded 7 purchases and 5 sales — net buying. Insider transactions are one signal among many and are often routine (option exercises or scheduled 10b5-1 sales), so Magnisto shows the raw feed for you to judge.
What is the forecast for Eli Lilly & Co. (LLY) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Eli Lilly & Co. (LLY), anchored to the current $1247.92 share price, so you can weigh the bull, base and bear cases for Eli Lilly & Co. side by side.
Is Eli Lilly & Co. (LLY) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Eli Lilly & Co. fits your own thesis and risk profile. This is research, not investment advice.